Supriya Lifescience Ltd
SUPRIYA Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
3 of 4 strong
The short version
- Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27. - Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD. - Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27. - Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years. - New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth. - Backward integration completed to support scalability and cost efficiency. - Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27. - Growth in U.S. - Supriya Lifescience targets approximately 20% annual revenue growth, aiming to reach INR1,000 crores by FY27.
From Supriya Lifescience Ltd's Q4 FY26 earnings-call transcript · updated 22 Jun 2026.
Revenue & Sales Performance
- Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27.
- Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD.
- Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27.
- Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years.
- New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth.
- Backward integration completed to support scalability and cost efficiency.
- Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Supriya Lifescience Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Continued capacity expansion with the addition of the F block at Lote Parshuram plant, adding 150-200 KL capacity over the next 2 years with INR40-50 crores capex.
- Development of the Patalganga facility with all clearances received; Phase 1 includes two API/advanced intermediate blocks and two formulation blocks, planned capex around INR200 crores over the next 2 years.
- Focus on capacity building to support growth, especially for CMO/CDMO opportunities and to handle scaling product volumes.
- Total capex for FY26 was INR152 crores, mainly spent on Ambernath facility, maintenance, Ribo Block, and formulation plant needs.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Supriya Lifescience Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Cardiovascular intermediate: Advanced discussions for 300 metric tons capacity, expected to be nearly fully utilized in FY27, but full potential to scale over 2-3 years.
- Contracts locked with 3-4 large customers for the cardiovascular product.
- Liquid anesthetic (sevoflurane formulation): CMO discussions at advanced stage, but no firm term sheet signed yet.
- DSM contract stabilized with around 3 tons/month volume; contributing approx. INR30-35 crores in FY26 with peak expected at INR60 crores in FY27.
- No signed agreement yet for GLP-1 product development; discussions are at an advanced stage.
- New product launches and existing basket growing steadily.
2 more points management made on order book & pipeline
Supriya Lifescience Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹277 Cr, net profit ₹74 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Supriya Lifesci.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Supriya Lifescience Ltd Q1 FY27 results?
- Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27. - Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD. - Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27. - Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years. - New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth. - Backward integration completed to support scalability and cost efficiency. - Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27. - Growth in U.S. - Supriya Lifescience targets approximately 20% annual revenue growth, aiming to reach INR1,000 crores by FY27.
What is Supriya Lifescience Ltd share price analysis?
Supriya Lifescience Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 29.9 with a market cap of ₹5,542. Investors should review the full earnings analysis for detailed insights.
Is Supriya Lifescience Ltd planning capital expenditure?
- Continued capacity expansion with the addition of the F block at Lote Parshuram plant, adding 150-200 KL capacity over the next 2 years with INR40-50 crores capex.
Keep Supriya Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.